

Resource Summary Report

Generated by PRECISE-TBI on Aug 9, 2026

Brilliant Violet 711(TM) anti-mouse CD3

RRID:AB_2563945

Type: Antibody

Proper Citation

BioLegend Cat# 100241, RRID:AB_2563945

Antibody Information

URL: http://antibodyregistry.org/AB_2563945

Proper Citation: BioLegend Cat# 100241, RRID:AB_2563945

Target Antigen: CD3

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 711(TM) anti-mouse CD3

Description: This monoclonal targets CD3

Target Organism: mouse

Clone ID: Clone 17A2

Antibody ID: AB_2563945

Vendor: BioLegend

Catalog Number: 100241

Record Creation Time: 20250819T225000+0000

Record Last Update: 20250820T032654+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 711(TM) anti-mouse CD3.

No alerts have been found for Brilliant Violet 711(TM) anti-mouse CD3.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 38 mentions in open access literature.

Listed below are recent publications. The full list is available at [PRECISE-TBI](#) .

Kourtesakis A, et al. (2026) A comparative analysis of CD70-directed CAR-T cells for glioblastoma treatment demonstrates a superior efficacy of the ligand-based construct. Molecular therapy. Oncology, 34(1), 201134.

González-Domínguez I, et al. (2026) Influenza B mosaic HA mRNA-LNP vaccines are cross-reactive and protective in mice. Molecular therapy. Nucleic acids, 37(2), 102921.

Ye K, et al. (2026) Direct interaction of V α 7 TCRs with IL17RA drives the differentiation of TH1-like $\alpha\alpha$ T cells. Science (New York, N.Y.), 393(6808), eadx9264.

Xu Y, et al. (2026) A dysregulated hepcidin-iron axis impairs antiviral immunity and induces lethal liver pathology in neonates. Immunity, 59(1), 79.

Lambert F, et al. (2025) Antibody-mediated TGF- β 1 activation for the treatment of diseases caused by deleterious T cell activity. Cell reports, 44(8), 116061.

Zhang FQ, et al. (2025) Zeaxanthin augments CD8+ effector T cell function and immunotherapy efficacy. Cell reports. Medicine, 6(9), 102324.

Cortez VS, et al. (2025) IL-25-induced memory type 2 innate lymphoid cells enforce mucosal immunity. Cell.

Haniuda K, et al. (2025) Mucosal viral infection elicits long-lived IgA responses via type 1 follicular helper T cells. Cell, 188(24), 6774.

Weis AM, et al. (2025) A capsular polysaccharide from a healthy human microbiota member activates a Lag-3-NK cell axis to restrain colon cancer and augment immunotherapy. Cell reports, 44(9), 116172.

Cortez VS, et al. (2025) IL-25-induced memory ILC2s mediate long-term small intestinal adaptation. bioRxiv : the preprint server for biology.

He C, et al. (2025) The balance between conventional and unconventional T follicular helper cells influences autoreactive B cell responses. Cell reports, 44(5), 115602.

Petry P, et al. (2025) Early microglia progenitors colonize the embryonic CNS via integrin-mediated migration from the pial surface. Developmental cell.

Corgnac S, et al. (2025) TGF- β and IL-12 conversely orchestrate the formation of CD103⁺ CD8 tumor-resident memory T cells to regulate response to therapeutic cancer vaccine. *iScience*, 28(8), 113147.

Thierry GR, et al. (2024) Non-classical monocytes scavenge the growth factor CSF1 from endothelial cells in the peripheral vascular tree to ensure survival and homeostasis. *Immunity*, 57(9), 2108.

González-Domínguez I, et al. (2024) Preclinical evaluation of a universal inactivated influenza B vaccine based on the mosaic hemagglutinin-approach. *NPJ vaccines*, 9(1), 222.

Wolter M, et al. (2024) Diet-driven differential response of *Akkermansia muciniphila* modulates pathogen susceptibility. *Molecular systems biology*, 20(6), 596.

Zhong J, et al. (2024) Distinct roles of TREM2 in central nervous system cancers and peripheral cancers. *Cancer cell*, 42(6), 968.

Slamanig S, et al. (2024) Intranasal SARS-CoV-2 Omicron variant vaccines elicit humoral and cellular mucosal immunity in female mice. *EBioMedicine*, 105, 105185.

Miyauchi S, et al. (2024) Protocol to study the immune profile of syngeneic mouse tumor models. *STAR protocols*, 5(3), 103139.

Delaunay T, et al. (2024) Exogenous non-coding dsDNA-dependent trans-activation of phagocytes augments anti-tumor immunity. *Cell reports. Medicine*, 5(5), 101528.